文献速递颈动脉与弓上血管

血管质量倡议中颈动脉支架置入经上肢与经股动脉及经颈动脉入路的院内结局比较

In-hospital outcomes after upper extremity versus transfemoral and transcarotid access for carotid stenting in the Vascular Quality Initiative.
PubMed 文献 · J Vasc Surg · 2022-07-14

倾向评分匹配后,经上肢入路较经股动脉或经颈动脉入路在有症状患者中院内卒中/死亡风险更高,主要由死亡风险驱动;无症状患者无差异。

要点

  • 经上肢入路较经股动脉入路死亡风险更高(2.4% vs 1.3%;RR 1.8;95%CI 1.1-3.1)。
  • 经上肢入路较经颈动脉入路卒中/死亡风险更高(4.2% vs 2.3%;RR 1.8;95%CI 1.2-2.7)。
  • 有症状患者中经上肢入路风险更高,无症状患者无差异。

核心结论

  • 与经股动脉或经颈动脉入路相比,经上肢入路在有症状患者中与更高的院内卒中/死亡风险相关,主要由死亡风险驱动;这些较差结局部分归因于经上肢入路患者术前神经功能障碍更严重;无症状患者中结局无差异;总体而言,研究结果强调经上肢入路中遵循指南指导的患者选择的重要性。

研究设计与样本

  • 回顾性队列研究,基于血管质量倡议注册研究2016年1月至2021年12月所有接受颈动脉支架置入的患者,比较经上肢入路与经股动脉入路或经颈动脉入路1:3倾向评分匹配队列的结局,并按颈动脉症状状态进行分层二次分析。

主要发现

  • 经上肢入路 vs 经股动脉入路匹配患者中,卒中/死亡风险无显著差异(4.1% vs 2.9%;RR 1.4;95%CI 0.95-2.1),但经上肢入路死亡风险更高(2.4% vs 1.3%;RR 1.8;95%CI 1.1-3.1)。
  • 有症状亚组中,经上肢入路 vs 经股动脉入路卒中/死亡风险更高(6.1% vs 3.9%;RR 1.6;95%CI 1.0-2.4),死亡风险更高(3.6% vs 1.7%;RR 2.1;95%CI 1.2-3.7);无症状患者中无差异。
  • 经上肢入路 vs 经颈动脉入路匹配患者中,卒中/死亡风险更高(4.2% vs 2.3%;RR 1.8;95%CI 1.2-2.7),死亡风险更高(2.4% vs 0.5%;RR 4.8;95%CI 2.4-9.5)。
  • 有症状亚组中,经上肢入路 vs 经颈动脉入路卒中/死亡风险更高(6.2% vs 2.4%;RR 2.6;95%CI 1.6-4.2),死亡风险更高(3.7% vs 0.7%;RR 5.6;95%CI 2.6-12);无症状患者中无差异。

临床怎么用

  • 作者认为,研究结果强调经上肢入路中遵循指南指导的患者选择的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Carotid artery stenting (CAS) is frequently used for patients at high risk for carotid endarterectomy. However, there are limited data comparing transradial or transbrachial (tr/tbCAS) access with more established CAS approaches. Therefore, we examined the effect of a tr/tbCAS approach versus a transfemoral (tfCAS) or transcarotid (TCAR) approach on outcomes after CAS. METHODS: We identified all patients undergoing CAS in the Vascular Quality Initiative registry from January 2016 to December 2021. We compared outcomes across 1:3 propensity score-matched cohorts of patients who underwent tr/tbCAS versus tfCAS or tr/tbCAS versus TCAR. As a secondary analysis, we assessed outcomes stratified by carotid symptom status. Our primary outcome was a composite end point of in-hospital stroke/death. RESULTS: Among 40,835 CAS patients, 962 (2.4%) underwent tr/tbCAS, 18,840 (46%) underwent tfCAS, and 21,033 (52%) underwent TCAR. Among matched patients who underwent tr/tbCAS versus tfCAS, there was no significant difference in the risk of stroke/death (4.1% vs 2.9%; relative risk [RR] 1.4; 95% confidence interval [CI], 0.95-2.1), but tr/tbCAS was associated with a higher risk of death (2.4% vs 1.3%; RR, 1.8; 95% CI, 1.1-3.1). In the symptomatic subgroup, tr/tbCAS was associated with a higher risk of stroke/death (6.1% vs 3.9%; RR, 1.6; 95% CI, 1.0-2.4) and death (3.6% vs 1.7%; RR, 2.1; 95% CI, 1.2-3.7), but there were no differences in asymptomatic patients. After adjustment for mRS in patients with preoperative stroke, there were no significant differences in stroke/death (RR, 1.1; 95% CI, 0.66-1.9) or death (RR, 1.6; 95% CI, 0.81-3.3) between groups. In matched patients who underwent tr/tbCAS versus TCAR, tr/tbCAS was associated with a higher risk of stroke/death (4.2% vs 2.3%; RR, 1.8; 95% CI, 1.2-2.7) and death (2.4% vs 0.5%; RR, 4.8; 95% CI, 2.4-9.5). In the symptomatic subgroup, tr/tbCAS remained associated with a higher risk of stroke/death (6.2% vs 2.4%; RR, 2.6; 95% CI, 1.6-4.2) and death (3.7% vs 0.7%; RR, 5.6; 95% CI, 2.6-12), but there were no differences in asymptomatic patients. After adjustment for Modified Rankin Scale in patients with preoperative stroke, there were no significant differences in stroke/death (RR, 1.4; 95% CI, 0.79-2.6) or death (RR, 2.3; 95% CI, 0.95-5.7) between groups. CONCLUSIONS: Compared with tfCAS or TCAR, tr/tbCAS was associated with a higher risk of in-hospital stroke/death in symptomatic patients, which was driven primarily by a higher risk of death. These inferior outcomes were partly attributable to more severe preoperative neurologic disability in tr/tbCAS patients. In contrast, there were no differences in outcomes in asymptomatic patients. Overall, our findings highlight the importance of guideline-directed patient selection in tr/tbCAS.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Marcaccio CL, Anjorin A, Patel PB, et al. In-hospital outcomes after upper extremity versus transfemoral and transcarotid access for carotid stenting in the Vascular Quality Initiative. J Vasc Surg. 2022. PMID: 35840075. doi:10.1016/j.jvs.2022.05.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。